|Bid||3.6200 x 1100|
|Ask||3.6500 x 1000|
|Day's Range||3.5500 - 3.6873|
|52 Week Range||3.1200 - 9.3000|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.33|
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has commenced enrollment and dosed the first subject in its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annual reconstitution of the Russell stock indexes, Moleculin has been selected to be added to the Russell 2000® Index effective after the close of the U.S. equity markets on June 25, 2021.
The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's (NASDAQ: MBRX) Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. It has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials to treat acute myeloid leukemia (AML). Phase 1b portion of the trial will determine the maximum-tolerated dose and safety of Annamycin, and Phase 2 will explore the efficacy of Annamycin as a single agent. A maximum of 25 subjects will be enrolled at the RP2D to evaluate efficacy further. The company also expects a second Phase 1b/2 trial of Annamycin in sarcoma lung metastases to be initiated in 2021. Price Action: MBRX shares are up 0.69% at $3.64 during the market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaEyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia StudyBristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.